New frontiers in nipping cancer in the bud

Penn Medicine is advancing cancer interception through a new vaccine development platform, leveraging immunology expertise and mRNA technology to create vaccines that could stop cancer before it develops by targeting precancerous growths. The initiative shifts from traditional prevention toward earlier intervention at the pre-malignant cell stage.